MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Sunday, March 3, 2019

Cleveland Clinic Chosen for Phase 2 Trial Testing NurOwn Stem Cell Therapy in Progressive MS Patients

February 26, 2019

BrainStorm Cell Therapeutics announced the Cleveland Clinic is the first clinical site contracted in the United States for the Phase 2 multi-center study evaluating the company’s NurOwn mesenchymal stem cell (MSC) therapy in individuals with progressive multiple sclerosis (MS).
“We are very excited to announce The Mellen Center for MS Treatment and Research at Cleveland Clinic as the first contracted U.S. clinical site for this very important Phase 2 progressive MS study that we plan to initiate in early 2019,” Chaim Lebovits, president and CEO of BrainStorm, said in a press release.
Stem cells can divide to self-renew and create different types of cells (a process called cell differentiation). The type of cells created during differentiation depend on the stem cell type and its cell potency (ability to become other cell types).
NurOwn trial request

MSCs are so-called multipotent stem cells derived from the bone marrow, that can transform into several types of cells. They form the basis of the NurOwn approach. NurOwn is designed to isolate patient-derived MSCs from the bone marrow, expand and change them into MSCs that secrete high levels of neurotrophic factors (NTFs — peptides or small proteins that support growth and survival of neurons).
These NTF-secreting MSCs (called MSC-NTF) can then be transplanted back to the same patient (autologous transplant), where they can deliver NTFs to the sites of neuronal damage. As a result, NTF-targeting to damaged neurons may slow or stabilize the disease’s progress.
“This is a crucial step forward toward rapidly enrolling a Phase 2 study to evaluate this innovative autologous cell therapy approach using our NurOwn technology platform in progressive MS patients,” Lebovits said.

To receive The MS BEACON, e-Newsletter, Click here

Click Red Box on banner to opt-in
Article Provided by:  #MSViewsandNews

No comments: